Search
Displaying 511–520 of 779 for “retinitis clinical trial”
-
Funded Foundation Fighting Blindness Grants and Awards for Fiscal Year 2022 (July 1, 2021–June 30, 2022)
-
Foundation News
The Foundation Fighting Blindness, the world’s leading organization committed to finding treatments and cures for retinal degenerative diseases, will host an online continuing medical education (CME and COPE) course on inherited retinal disease gene therapies on Thursday, June 9, 2022, at 7:00 p.m. EDT.
-
Foundation News
The inaugural credit-based event will include education on inherited retinal diseases, physician resources, and current clinical trials.
-
What Does the Foundation's Statement of Financial Position Mean?
First and foremost, it means the Foundation Fighting Blindness (FFB) is in a strong position to continue to fund the most promising research on potential cures for retinal degenerative diseases and to help bring groundbreaking discoveries to clinical trials and the U.S. Food and Drug Administration (FDA) approval process.
-
Foundation Commits $2 Million to Development of a Cross-Cutting Drug Treatment
NewsMitoChem Therapeutics has identified three compounds that appear to boost mitochondrial function and, thus, show potential for slowing vision loss caused by a variety of retinal degenerations.
-
MeiraGTx Acquires XLRP Gene Therapy Bota-Vec, Moves Toward Regulatory Filing
Research NewsMeiraGTx has acquired bota-vec, a gene therapy for X-linked retinitis pigmentosa (XLRP), and plans to file for regulatory approval in the U.S., Europe, and Japan, with a potential launch in 2027.
-
Story Update: Seeing Through Your Disability
Beacon StoriesLance Johnson shares life with retinitis pigmentosa (RP) as a creator, father, and Foundation Fighting Blindness ambassador—advocating for awareness and advancing treatments and cures.
-
Invisible Disability
I find it difficult to explain my eyesight to people. I have retinitis pigmentosa (RP), which is a condition that progressively causes vision loss. I am legally blind, my peripheral vision is very limited, and most of what I see is blurry.
-
Research News
The five-year grant will advance the emerging treatments toward clinical trials
-
Research News
The company is currently developing programs for Stargardt disease (ABCA4), Usher syndrome, RP25 (EYS), and RP1.
